BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc. (Profectus), a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today it has received a commitment of additional funding from the PATH Malaria Vaccine Initiative (MVI). The funds will support proof-of-concept studies in non-human primates with proprietary, plasmid DNA (pDNA, delivered using the electroporation (EP) based TriGrid™delivery system (TriGrid) developed by Ichor Medical Systems) and recombinant vesicular stomatitis virus (rVSV) vector technologies towards the development of a preventive malaria vaccine.
